Surf Wiki
Save to docs
general/alpha-glucosidase-inhibitors

From Surf Wiki (app.surf) — the open knowledge base

Voglibose

Alpha-glucosidase inhibitor

Summary

Alpha-glucosidase inhibitor

| Drugs.com = | elimination_half-life = Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three major drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.

Efficacy

A Cochrane systematic review assessed the effect of alpha-glucosidase inhibitors in people with impaired glucose tolerance, impaired fasting blood glucose, elevated glycated hemoglobin A1c (HbA1c). It was found that there was no conclusive evidence that voglibose compared to diet and exercise or placebo reduced incidence of diabetes mellitus type 2, improved all-cause mortality, reduced or increased risk of cardiovascular mortality, serious or non-serious adverse events, non-fatal stroke, congestive heart failure, or non-fatal myocardial infarction.

References

References

  1. (2006). "Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors". Current Medicinal Chemistry.
  2. (December 2013). "Voglibose: an alpha glucosidase inhibitor". Journal of Clinical and Diagnostic Research.
  3. "Voglibose". Springer Nature Switzerland AG.
  4. (December 2018). "Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews.
Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

alpha-glucosidase-inhibitors amino-sugars
Want to explore this topic further?

Ask Mako anything about Voglibose — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report